Clinical trials: Salivary Cancer
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
High-grade Salivary Gland Carcinoma, High-grade Salivary Gland Mucoepidermoid Carcinoma
Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent and/or metastatic adenoid cystic cancer or other salivary gland cancers.
- Conditions
- High-grade Salivary Gland Carcinoma, High-grade Salivary Gland Mucoepidermoid Carcinoma, Low-grade Salivary Gland Carcinoma, Low-grade Salivary Gland Mucoepidermoid Carcinoma
- Trial name
- NCT00095563
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer).
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IVA Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01604772
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 51 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00095628
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT00492089
- Testing
- bevacizumab, magnetic resonance imaging, quality-of-life assessment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Head and Neck Cancer
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphedema
- Trial name
- AMWELL-SL (NCT00828516)
- Testing
- Acupuncture and moxibustion
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- East and North Hertfordshire NHS Trust
Breast Cancer, Colorectal Cancer
Validation of a Screening Tool in Geriatric Oncology
RATIONALE: A screening questionnaire may help doctors plan better treatment for older patients with cancer. PURPOSE: This clinical trial is studying a questionnaire in screening older patients with cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- ONCODAGE (NCT00963911)
- Testing
- Geriatric screening tests, Multidimensional geriatric assessment
- Where
- France
- Volunteers
- 1,674 people
- Sponsor
- Institut Bergonié
Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
This phase II trial studies how well enzalutamide works in treating patients with androgen receptor positive salivary cancers that have spread from where it started to nearby tissue or lymph nodes (locally advanced) or have…
- Conditions
- Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma
- Trial name
- NCT02749903
- Testing
- enzalutamide
- Where
- 287 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced)…
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage III Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01175980
- Testing
- Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.
- Conditions
- Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer
- Trial name
- NCT01613768
- Testing
- eribulin mesylate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This pilot randomized phase I/II trial studies the side effects and best dose of PI3K inhibitor BKM120 when given together with cetuximab and to see how well it works in treating patients with recurrent or metastatic head and…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01816984
- Testing
- PI3K inhibitor BKM120, cetuximab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body.
- Conditions
- Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT00859937
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 34 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
This phase II trial studies how well giving temsirolimus together with cetuximab works compared to temsirolimus alone in treating patients with recurrent and/or metastatic head and neck cancer who did not respond to previous…
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- MAESTRO HN (NCT01256385)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 24 sites in United States, China
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors.
- Trial name
- NCT02047253
- Testing
- Carfilzomib, Dexamethasone, Acyclovir
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Salivary Gland Cancer
Iressa Study in Patients With Salivary Gland Cancer
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
- Trial name
- NCT00509002
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment
Primary Objective: To determine if amifostine in combination with IMRT can mitigate the decrease in production of saliva by the submandibular and sublingual salivary glands in patients with HNSCC. Secondary Objectives: 1.
- Trial name
- NCT00409331
- Testing
- Amifostine, Intensity- Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00509665
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina